课题基金 / 基金详情

Advanced Artificial Pancreas Systems to Enable Fully Automated Glycemic Control in Type 1 Diabetes Mellitus

Advanced Artificial Pancreas Systems to Enable Fully Automated Glycemic Control in Type 1 Diabetes Mellitus
先进的人工胰腺系统可实现 1 型糖尿病的全自动血糖控制
批准号:
10676903
负责人:
MARC D BRETON
金额:
$65.8万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-09-12 至 2026-07-31

项目摘要

项目成果

MARC D BRETON的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要
英文摘要
PROJECT ABSTRACT Despite advancements in automated insulin delivery systems that demonstrate superior glycemic outcomes, challenging clinical issues remain with the continued need for accurate carbohydrate counting and meal announcement combined with slow-acting subcutaneous insulin that contribute to repeated occurrences of postprandial hyperglycemia. This clinical gap in glycemic control is addressed by the proposed project. We intend to leverage our existing advancements in pattern recognition and anticipation to refine and test a fully automated closed-loop system that does not require meal announcements. This system is unique in that it relies on pattern recognition, particularly surrounding meals, in an anticipatory manner so that insulin action is taken in advance of an expected meal rather than the predominantly reactive solutions that are often proposed. We intend to further test and tune this system within the context of accelerated insulins to further improve glycemic outcomes and remove barriers to use of these systems by lowering burden of disease management. We have already developed the foundational tools needed for a fully automated closed-loop and will plan for further refinement by leveraging data from our accumulated clinical studies database. We plan to conduct 2 pilots studies followed by a larger, 7-month main study to evaluate the following specific aims of this proposal: 1) We hypothesize that novel faster acting insulin analogs can be safely used to provide more effective fully automated closed-loop control. Our first pilot will test the differences between Fiasp and a novel formulation of aspart (AT247) in a supervised trial. This trial results will inform the selection of the insulin used in the subsequent trials. 2) We hypothesize that, with a design adapted to these new insulin formulations, fully automated closed-loop control is a valid clinical alternative to hybrid closed-loop systems, the current state- of-the-art systems. 3) Lastly, we hypothesize that further adding glycemic disturbance anticipation (e.g. generally surrounding meals) to this fully automated closed-loop control system will further improve glycemic outcomes compared with a fully automated closed-loop system without disturbance anticipation.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
Use of an Ultrarapid Acting Insulin Analog with Control-IQ: A Case Report.
使用超速效胰岛素类似物与 Control-IQ:病例报告。
DOI: 10.1089/dia.2022.0192
发表时间: 2022
期刊: Diabetes technology & therapeutics
影响因子: 5.4
作者: [Schoelwer,MelissaJ, DeBoer,MarkD, Breton,MarcD, Kovatchev,BorisP]
通讯作者: Kovatchev,BorisP
Performance Effect of Adjusting Insulin Sensitivity for Model-Based Automated Insulin Delivery Systems.
调整胰岛素敏感性对基于模型的自动胰岛素输送系统的性能影响。
DOI: 10.1177/19322968231206798
发表时间: 2023
期刊: Journal of diabetes science and technology
影响因子: 5
作者: [Moscoso-Vasquez,Marcela, Fabris,Chiara, Breton,MarcD]
通讯作者: Breton,MarcD
Integration of a Safety Module to Prevent Rebound Hypoglycemia in Closed-Loop Artificial Pancreas Systems.
集成安全模块以防止闭环人工胰腺系统中出现低血糖反弹。
DOI: 10.1177/19322968231212205
发表时间: 2024
期刊: Journal of diabetes science and technology
影响因子: 5
作者: [Villa-Tamayo,MaríaF, Colmegna,Patricio, Breton,MarcD]
通讯作者: Breton,MarcD
DOI: 10.2337/dc23-0119
发表时间: 2023-09-01
期刊: DIABETES CARE
影响因子: 16.2
作者: [Garcia-Tirado, Jose, Colmegna, Patricio, Villard, Orianne, Diaz, Jenny L., Esquivel-Zuniga, Rebeca, Koravi, Chaitanya L. K., Barnett, Charlotte L., Oliveri, Mary C., Fuller, Morgan, Brown, Sue A., Deboer, Mark D., Breton, Marc D.]
通讯作者: Breton, Marc D.
Advanced Artificial Pancreas Systems to Enable Fully Automated Glycemic Control in Type 1 Diabetes Mellitus
  • 批准号:
    10276560
  • 项目类别:
  • 资助金额:
    $68.6万
  • 财政年份:
    2021
  • 负责人:
    MARC D BRETON
  • 依托单位:
Advanced Artificial Pancreas Systems to Enable Fully Automated Glycemic Control in Type 1 Diabetes Mellitus
  • 批准号:
    10488207
  • 项目类别:
  • 资助金额:
    $67.18万
  • 财政年份:
    2021
  • 负责人:
    MARC D BRETON
  • 依托单位:
Artificial Pancreas - Adolescent Physiology and Psychology Longitudinal Evaluation (A.P. APPLE)
  • 批准号:
    10381710
  • 项目类别:
  • 资助金额:
    $63.89万
  • 财政年份:
    2020
  • 负责人:
    MARC D BRETON
  • 依托单位:
海外基金